InterSystems and Google Cloud Integrate InterSystems HealthShare with Google Cloud’s Healthcare API
InterSystems, a creative data technology provider managing over one billion health records worldwide, today announced a new partnership that integrates InterSystems HealthShare with Google Cloud. Announced at HLTH, this collaboration aims to deliver a scalable, real-time, harmonized data foundation for generative and agentic AI applications.
The partnership addresses one of the most pressing challenges in healthcare IT: fragmented and inconsistent data. By combining InterSystems expertise in data harmonization, identity resolution, and interoperability with Google Cloud’s broad suite of AI-enabled analytics and search capabilities and secure infrastructure, healthcare organizations can now unlock the full potential of AI with clean, unified, and actionable data on a proven, enterprise-grade cloud platform.
“AI is transforming healthcare, but it can only succeed when it’s grounded in reliable, actionable data,” said Don Woodlock, head of Global Healthcare Solutions at InterSystems. “By integrating HealthShare into Google Cloud’s comprehensive health data and AI ecosystem, we are helping organizations ensure their data is interoperable and responsibly managed. This means providers can focus on improving workflows and delivering smarter care.”
InterSystems HealthShare provides aggregation, normalization, de-duplication, patient identity resolution, terminology mapping, and EHR-specific accelerators across diverse data sources. Integrated into Google Cloud’s Healthcare API, these capabilities empower customers to:
Build a Scalable Data Foundation: Create a harmonized and FHIR-ready data foundation for research, operations, and clinical decision-making, leveraging the power of Google Cloud's AI Optimized infrastructure and BigQuery for massive-scale analytics.
Leverage Advanced AI: Utilize leading generative and agentic AI models, including the Gemini family of models, on Google Cloud's Vertex AI platform for decision support, administrative automation, and population health initiatives.
Improve Interoperability and Security: Enhance data exchange with existing systems and standards to enable coordinated care, all while benefiting from Google Cloud’s industry-leading security and compliance framework.
“Healthcare organizations want to adopt AI solutions that are safe, responsible, and immediately useful,” said Aashima Gupta, global director, Healthcare Strategy & Solutions, Google Cloud. “InterSystems is delivering a platform that simplifies data preparation and enables organizations to unlock the full value of their information by combining HealthShare’s unique data curation with Google Cloud's advanced data processing and AI/ML capabilities."
The offering is available immediately through a bring-your-own-license (BYOL) model, with Google Cloud Marketplace availability in North America expected in Q1 2026 and global rollout to follow. For more information, please visit our partner website.
About InterSystems
InterSystems, a creative data technology provider, delivers a unified foundation for next-generation applications for healthcare, finance, manufacturing, and supply chain customers in more than 80 countries. Our data platforms solve interoperability, speed, and scalability problems for large organizations around the globe to unlock the power of data and allow people to perceive data in imaginative ways. Established in 1978, InterSystems is committed to excellence through its 24×7 support for customers and partners around the world. Privately held and headquartered in Boston, Massachusetts, InterSystems has 38 offices in 28 countries worldwide. For more information, please visit InterSystems.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251020786501/en/
Contacts
InterSystems PR Contact:
Zach Keating
pr@intersystems.com
617.551.5158
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom